Get the Stockscreener App
4.04
0.98%
-0.04
After Hours:
4.01
-0.03
-0.74%
X 4 Pharmaceuticals Inc stock is traded at $4.04, with a volume of 460.29K.
It is down -0.98% in the last 24 hours and up +2.54% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.08
Open:
$4.1
24h Volume:
460.29K
Relative Volume:
1.16
Market Cap:
$381.05M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.8902
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
+4.94%
1M Performance:
+2.54%
6M Performance:
+8.89%
1Y Performance:
+47.99%
1-Day Range:
$3.99
$4.145
1-Week Range:
$3.67
$4.145
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.04 | 384.82M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
FDA Recalls and Warnings: Gas-X Contaminated With Coolant; More Generic Cymbalta Cancer Risks, Supplements Linked to Salmonella Outbreak - MedShadow Foundation
ALERT: NAFDAC warns Nigerians against contaminated children’s drug recalled in US - TheCable
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
KalVista (NASDAQ: KALV) director options cashed out, canceled in Chiesi deal - Stock Titan
KalVista (KALV) director closes out 91,000 options in $27-per-share Chiesi merger - Stock Titan
KalVista (KALV) director’s stock options cancelled or cash-settled in Chiesi takeover - Stock Titan
KalVista (NASDAQ: KALV) CMO’s stock, RSUs and options cancelled in $27-per-share Chiesi merger cleanup - Stock Titan
KalVista (KALV) director has 45,000 stock options cashed out in Chiesi merger terms - Stock Titan
KalVista (NASDAQ: KALV) director’s options canceled and cashed out in $27 Chiesi deal - Stock Titan
KalVista (KALV) CCO Sweeny cashes out stock, RSUs and options in Chiesi buyout - Stock Titan
KalVista (NASDAQ: KALV) COO’s RSUs and options cashed out in Chiesi merger - Stock Titan
Chiesi deal cancels options for KalVista (KALV) director Edward Unkart - Stock Titan
KalVista (NASDAQ: KALV) CEO equity cancelled for $27 cash deal - Stock Titan
KalVista (NASDAQ: KALV) CDO disposes equity in $27-per-share Chiesi deal - Stock Titan
KalVista Pharmaceuticals (KALV) CFO exits equity as Chiesi cash deal closes - Stock Titan
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Fulcrum shrinks headcount 85% - Fierce Biotech
Vivo Opportunity entities (INM) add 249,227 InMed shares in open-market buys - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - TradingView
Supreme Court Clarifies Pleading Standard for Induced Infringement in Hikma v. Amarin - JD Supra
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | MintzIntellectual Property Viewpoints - JD Supra
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - markets.businessinsider.com
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ADHD medication shortage reported by pharmaceutical companies - FOX Carolina News
XFOR: Advancing an oral therapy for chronic neutropenia with pivotal data in 2027 and FDA approval targeted for 2028 - TradingView
Justice Jackson Pens Unanimous Decision Backed by SCOTUS Conservatives - Newsweek
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - TradingView
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Alnylam (ALNY) director sells 3,830 shares after expiring option exercise - Stock Titan
Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
XFOR Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink initiates X4 Pharmaceuticals stock with outperform rating - Investing.com
Leerink Partners Initiates X4 Pharmaceuticals(XFOR.US) With Buy Rating, Announces Target Price $12 - Moomoo
Leerink Partners Initiates X4 Pharmaceuticals at Outperform With $12 Price Target - marketscreener.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FULL HOUSE RESORTS TO BREAK GROUND ON THE PERMANENT AMERICAN PLACE CASINO - Weekly Voice
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):